ImmuCell Corporation - Asset Resilience Ratio

Latest as of December 2024: 0.11%

ImmuCell Corporation (ICCC) has an Asset Resilience Ratio of 0.11% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ICCC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$50.40K

Cash + Short-term Investments

Total Assets

$45.10 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2002–2021)

This chart shows how ImmuCell Corporation's Asset Resilience Ratio has changed over time. See ICCC net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down ImmuCell Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ICCC company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$50.40K	0.11%
Total Liquid Assets	$50.40K	0.11%

Asset Resilience Insights

Limited Liquidity: ImmuCell Corporation maintains only 0.11% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ImmuCell Corporation Industry Peers by Asset Resilience Ratio

Compare ImmuCell Corporation's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for ImmuCell Corporation (2002–2021)

The table below shows the annual Asset Resilience Ratio data for ImmuCell Corporation.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	0.00%	$-468.00	$44.47 Million	-2.47pp
2020-12-31	2.47%	$996.50K	$40.35 Million	-3.94pp
2019-12-31	6.41%	$2.48 Million	$38.69 Million	--
2017-12-31	0.00%	$0.00	$34.30 Million	--
2016-12-31	22.16%	$5.47 Million	$24.70 Million	-8.41pp
2015-12-31	30.57%	$4.46 Million	$14.60 Million	+8.05pp
2014-12-31	22.52%	$2.49 Million	$11.05 Million	-4.71pp
2013-12-31	27.23%	$2.98 Million	$10.96 Million	+6.93pp
2012-12-31	20.31%	$2.24 Million	$11.03 Million	-17.70pp
2011-12-31	38.01%	$4.18 Million	$10.99 Million	+8.00pp
2010-12-31	30.02%	$3.23 Million	$10.75 Million	-6.14pp
2009-12-31	36.16%	$3.61 Million	$9.98 Million	-1.90pp
2008-12-31	38.05%	$3.85 Million	$10.13 Million	-2.46pp
2007-12-31	40.52%	$4.22 Million	$10.41 Million	-5.82pp
2006-12-31	46.33%	$5.27 Million	$11.36 Million	+6.66pp
2005-12-31	39.68%	$3.95 Million	$9.96 Million	+10.82pp
2004-12-31	28.85%	$2.75 Million	$9.53 Million	+18.00pp
2003-12-31	10.85%	$888.32K	$8.19 Million	+0.38pp
2002-12-31	10.48%	$787.05K	$7.51 Million	--

pp = percentage points

About ImmuCell Corporation

NASDAQ:ICCC USA Biotechnology

Market Cap

$84.90 Million

Market Cap Rank

#19909 Global

#4472 in USA

Share Price

$9.39

Change (1 day)

+0.05%

52-Week Range

$4.56 - $10.63

All Time High

$11.88